Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | BCL9 | O00512 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235945 | 0.84 | BCL9 (0.65) | HTR2ABCL9CTNNB1ALDH1A1TDP1 | |
| SCHEMBL2236491 | 0.84 | HTR2A (0.52) | HTR2ABCL9CTNNB1ALDH1A1MAPT | |
| SCHEMBL2236482 | 0.82 | BCL9 (0.53) | HTR2ABCL9CTNNB1ALDH1A1TDP1 | |
| SCHEMBL3423118 | 0.79 | HTR2A (0.61) | HTR2ABCL9CTNNB1ALDH1A1MAPT | |
| SCHEMBL9846632 | 0.78 | HTR2A (0.55) | HTR2ABCL9CTNNB1ALDH1A1TDP1 | |
| SCHEMBL2233848 | 0.78 | HTR2A (0.50) | HTR2ABCL9CTNNB1ALDH1A1MAPT | |
| SCHEMBL2235180 | 0.77 | BCL9 (0.48) | HTR2ABCL9CTNNB1ALDH1A1TDP1 | |
| SCHEMBL12348669 | 0.75 | BCL9 (0.46) | HTR2ABCL9CTNNB1ALDH1A1MAPT | |
| SCHEMBL5764186 | 0.74 | HTR2A (0.61) | HTR2ABCL9CTNNB1ALDH1A1MAPT | |
| SCHEMBL2235530 | 0.74 | HTR2A (0.54) | HTR2ABCL9CTNNB1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3075722-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | Xgene Pharmaceutical Inc (KY) | 2016-10-05 | — | — | EP | disclosed |
| US-20160256558-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | KYPHIA PHARMACEUTICALS, INC. (KY) | 2016-09-08 | — | — | US | disclosed |
| US-20160256558-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | KYPHIA PHARMACEUTICALS, INC. (KY) | 2016-09-08 | — | — | US | disclosed |
| EP-2344447-B1 | GABA CONJUGATES AND METHODS OF USE THEREOF | XGENE PHARMACEUTICAL INC (KY) | 2016-06-08 | — | — | EP | disclosed |
| US-9186341-B2 | GABA conjugates and methods of use thereof | KYPHIA PHARMACEUTICALS, INC. (KY) | 2015-11-17 | — | — | US | disclosed |
| US-9186341-B2 | GABA conjugates and methods of use thereof | KYPHIA PHARMACEUTICALS, INC. (KY) | 2015-11-17 | — | — | US | disclosed |
| US-20130035352-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | KYPHIA PHARMACEUTICALS, INC. (KY) | 2013-02-07 | — | — | US | disclosed |
| US-20130035352-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | KYPHIA PHARMACEUTICALS, INC. (KY) | 2013-02-07 | — | — | US | disclosed |
| US-8268887-B2 | Drug conjugates and methods of use thereof | KYPHIA PHARMACEUTICALS, INC. (KY) | 2012-09-18 | — | — | US | disclosed |
| US-8268887-B2 | Drug conjugates and methods of use thereof | KYPHIA PHARMACEUTICALS, INC. (KY) | 2012-09-18 | — | — | US | disclosed |
| US-20100113497-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | KYPHIA PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113497-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | KYPHIA PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2010042759-A2 | GABA CONJUGATES AND METHODS OF USE THEREOF | KYPHIA PHARMACEUTICALS INC (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035352-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | GABRA5, GABRB3, GABRB2 | HTR2A 560/4885BCL9 4156/4885CTNNB1 4247/4885 |
| US-20160256558-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | GABRA5, GABRB3, GABRB2 | HTR2A 560/4885BCL9 4156/4885CTNNB1 4247/4885 |
| US-20100113497-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | GABRA5, GABRB3, GABRB2 | HTR2A 560/4885BCL9 4156/4885CTNNB1 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.